On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy

被引：12

作者：

Murata, Ayato ^{[1
]}

Amano, Nozomi ^{[1
]}

Sato, Sho ^{[1
]}

Tsuzura, Hironori ^{[1
]}

Tomishima, Ko ^{[1
]}

Sato, Shunsuke ^{[1
]}

Matsumoto, Kohei ^{[1
]}

Shimada, Yuji ^{[1
]}

Iijima, Katsuyori ^{[1
]}

Genda, Takuya ^{[1
]}

机构：

[1] Juntendo Univ, Shizuoka Hosp, Dept Gastroenterol & Hepatol, Shizuoka 4102295, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 06期

关键词：

chronic hepatitis B; hepatocellular carcinoma; Mac-2-binding protein glycosylation isomer; nucleot(s)ide analog; risk factor; NATURAL-HISTORY; VIRUS INFECTION; VARIABILITY;

D O I：

10.3390/ijms21062051

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We aimed to analyze the serum level of a novel fibrosis marker, Mac-2-binding protein glycosylation isomer (M2BPGi), and its predictive value for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) under nucleot(s)ide analogue (NA) therapy. Serum M2BPGi levels were quantified in 147 CHB patients at baseline, 48 weeks after starting NA therapy, and at the patients' last visit. The serum M2BPGi level serially decreased at each time point. During the median follow-up time of 6.6 years, 14 of 147 patients developed HCC. Multivariate Cox proportional hazard analysis demonstrated that high serum M2BPGi at 48 weeks was an independent risk factor for HCC development. A cutoff value of M2BPGi at 48 weeks > 1.5 showed an adjusted hazard ratio = 34.9 (95% confidence interval, 4.3-284.9). The 3- and 5-year cumulative incidence of HCC in patients with low M2BPGi were 0.9% and 4.2%, respectively, whereas those in patients with high M2BPGi were 10.1% and 25.6%, respectively (p < 0.001). In conclusion, Serum M2BPGi level at 48 weeks is a useful predictor for HCC development in patients with CHB who receive NA therapy.

引用

页数：10

共 21 条

[1] JS']JSH Guidelines for the Management of Hepatitis B Virus Infection [J].

Asahina, Yasuhiro ;

Hayashi, Norio ;

Hiramatsu, Naoki ;

Izumi, Namiki ;

Koike, Kazuhiko ;

Kumada, Hiromitsu ;

Kurosaki, Masayuki ;

Oketani, Makoto ;

Suzuki, Fumitaka ;

Takikawa, Hajime ;

Tanaka, Atsushi ;

Tanaka, Eiji ;

Tanaka, Yasuhito ;

Tsubouchi, Hirohito ;

Yotsuyanagi, Hiroshi .

HEPATOLOGY RESEARCH, 2014, 44 :1-58

[2] Sampling variability of liver fibrosis in chronic hepatitis C [J].

Bedossa, P ;

Dargère, D ;

Paradis, V .

HEPATOLOGY, 2003, 38 (06) :1449-1457

[3] Current concepts: Liver biopsy. [J].

Bravo, AA ;

Sheth, SG ;

Chopra, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :495-500

[4] Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B [J].

Chang, Ting-Tsung ;

Liaw, Yun-Fan ;

Wu, Shun-Sheng ;

Schiff, Eugene ;

Han, Kwang-Hyub ;

Lai, Ching-Lung ;

Safadi, Rifaat ;

Lee, Samuel S. ;

Halota, Waldemar ;

Goodman, Zachary ;

Chi, Yun-Chan ;

Zhang, Hui ;

Hindes, Robert ;

Iloeje, Uchenna ;

Beebe, Suzanne ;

Kreter, Bruce .

HEPATOLOGY, 2010, 52 (03) :886-893

[5] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].

Chen, CJ ;

Yang, HI ;

Su, J ;

Jen, CL ;

You, SL ;

Lu, SN ;

Huang, GT ;

Iloeje, UH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73

[6] Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences [J].

Ganem, D ;

Prince, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1118-1129

[7] Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection [J].

Hosaka, Tetsuya ;

Suzuki, Fumitaka ;

Kobayashi, Masahiro ;

Seko, Yuya ;

Kawamura, Yusuke ;

Sezaki, Hitomi ;

Akuta, Norio ;

Suzuki, Yoshiyuki ;

Saitoh, Satoshi ;

Arase, Yasuji ;

Ikeda, Kenji ;

Kobayashi, Mariko ;

Kumada, Hiromitsu .

HEPATOLOGY, 2013, 58 (01) :98-107

[8] Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B [J].

Kawaguchi, Kazunori ;

Honda, Masao ;

Ohta, Hajime ;

Terashima, Takeshi ;

Shimakami, Tetsuro ;

Arai, Kuniaki ;

Yamashita, Taro ;

Sakai, Yoshio ;

Yamashita, Tatsuya ;

Mizukoshi, Eishiro ;

Komura, Takuya ;

Unoura, Masashi ;

Kaneko, Shuichi .

JOURNAL OF GASTROENTEROLOGY, 2018, 53 (06) :740-751

[9] Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response [J].

Kim, G. -A. ;

Han, S. ;

Kim, H. -D. ;

An, J. ;

Lim, Y. -S. .

JOURNAL OF VIRAL HEPATITIS, 2017, 24 (11) :990-997

[10] A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis [J].

Kuno, Atsushi ;

Ikehara, Yuzuru ;

Tanaka, Yasuhito ;

Ito, Kiyoaki ;

Matsuda, Atsushi ;

Sekiya, Satoru ;

Hige, Shuhei ;

Sakamoto, Michiie ;

Kage, Masayoshi ;

Mizokami, Masashi ;

Narimatsu, Hisashi .

SCIENTIFIC REPORTS, 2013, 3

← 1 2 3 →